cat no | ioEA1006
ioGlutamatergic Neurons
TDP‑43 M337V/WT
Human iPSC-derived ALS and FTD disease model
A rapidly maturing, consistent and scalable isogenic system to study amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
ioGlutamatergic Neurons TDP‑43 M337V/WT are opti‑ox deterministically programmed glutamatergic neurons carrying a genetically engineered heterozygous M337V mutation in the TARDBP gene, encoding TAR DNA binding protein 43 (TDP‑43).
Place your order
Confidently investigate your phenotype of interest across multiple clones with our disease model clone panel. Detailed characterisation data (below) and bulk RNA sequencing data (upon request) help you select specific clones if required.
Benchtop benefits
Make True Comparisons
Pair the ioDisease Model Cells with the genetically matched wild-type ioGlutamatergic Neurons to investigate the impact of mutant TDP‑43 protein on disease progression.
Scalable
Industrial scale quantities are available with industry-leading seeding densities, and at a price point that allows the cells to be used from research to high throughput screening.
Quick
The disease model cells and genetically matched control are experiment ready as early as 2 days post revival, and form structural neuronal networks at 11 days.
Highly characterised and defined
ioGlutamatergic Neurons TDP‑43 M337V/WT express neuron-specific markers comparably to the wild type control
Immunofluorescent staining on day 11 post-revival demonstrates similar homogenous expression of pan-neuronal proteins MAP2 and TUBB3 (upper panel) and glutamatergic neuron-specific transporter VGLUT2 (lower panel) in ioGlutamatergic Neurons TDP‑43 M337V/WT compared to the genetically matched control. 100X magnification.
ioGlutamatergic Neurons TDP‑43 M337V/WT form structural neuronal networks by day 11
ioGlutamatergic Neurons TDP‑43 M337V/WT mature rapidly, show glutamatergic neuron morphology and form structural neuronal networks over 11 days when compared to the genetically matched control. Day 1 to 11 post-thawing; 100X magnification.
ioGlutamatergic Neurons TDP‑43 M337V/WT demonstrate gene expression of neuronal-specific and glutamatergic-specific markers following deterministic programming
Gene expression analysis demonstrates that ioGlutamatergic Neurons TDP‑43 M337V/WT and the wild-type, genetically matched control (WT) lack the expression of pluripotency makers (NANOG and OCT4), at day 11, while robustly expressing pan-neuronal (TUBB3 and SYP) and glutamatergic-specific (VGLUT1 and VGLUT2) markers, and the glutamate receptor GRIA4. Gene expression levels were assessed by RT-qPCR (data normalised to HMBS; cDNA samples of the parental human iPSC line (hiPSC Control) were included as reference). Data represents day 11 post-revival samples, n=2 replicates.
Disease-related TARDBP is expressed in ioGlutamatergic Neurons TDP‑43 M337V/WT following deterministic programming
Gene expression analysis demonstrates that ioGlutamatergic Neurons TDP‑43 M337V/WT and the wild-type, genetically matched control (WT) express the TARDBP gene encoding TDP‑43. Gene expression levels were assessed by RT-qPCR (data normalised to HMBS; cDNA samples of the parental human iPSC line (hiPSC Control) were included as reference). Data represents day 11 post-revival samples, n=2 replicates.
Disease-related phenotype
Differences in neuronal activity between disease models and control cells by MEA analysis indicates the potential of the panel as a relevant translational in vitro drug discovery model for ALS and FTD
Reduced neuronal activity was measured in ioGlutamatergic Neurons TDP-43 M337V/M337V compared to ioGlutamatergic Neurons TDP-43 M337V/WT and the genetically matched control, ioGlutamatergic Neurons.
Microelectrode array (MEA) chips were spotted with 100K (~900K cells/cm2) ioGlutamatergic Neurons (WT), TDP-43 M337V/WT, or TDP-43 M337V/M337V, along with 20K (~180K cells/cm2) human iPSC-derived astrocytes.
Brightfield at 26 DIV (A, left), cells show good coverage of electrodes and produce clear burst and network burst activity as seen in the raster plot of activity (A, right). In the raster plot, each dash indicates a firing event, blue indicates a single electrode burst and the pink box indicates a network burst event.
Quantification of raster plots over the course of culture shows that ioGlutamatergic Neurons TDP-43 M337V/M337V have a lower weighted mean firing rate, and network burst frequency than WT and ioGlutamatergic Neurons TDP-43 M337V/WT (B). No clear difference is noted between WT and TDP-43 M337V/WT. Error bars indicate SEM, n=14 technical repeats.
Data courtesy of Charles River Laboratories.
Cells arrive ready to plate
ioGlutamatergic Neurons TDP‑43 M337V/WT are delivered in a cryopreserved format and are programmed to mature rapidly upon revival in the recommended media. The protocol for the generation of these cells is a two-phase process: Phase 1, Stabilisation for 4 days; Phase 2, Maintenance, during which the neurons mature. Phases 1 and 2 after revival of cells are carried out by the customer.
Industry leading seeding density
Do more with every vial
The recommended minimum seeding density is 30,000 cells/cm2, compared to up to 250,000 cells/cm2 for other similar products on the market. One small vial can plate a minimum of 0.7 x 24-well plate, 1 x 96-well plate, or 1.5 x 384-well plates. One large vial can plate a minimum of 3.6 x 24-well plates, 5.4 x 96-well plates, or 7.75 x 384-well plates. This means every vial goes further, enabling more experimental conditions and more repeats, resulting in more confidence in the data.
.png?width=604&name=Tech%20Nets%20online%20symposium%20header%20(1).png)
_MAP2(R)_DAPI(B)_%20(1).png?width=604&name=a-HTT50CAGWT_Overlay__TUBB3(G)_MAP2(R)_DAPI(B)_%20(1).png)
_MAP2(R)_Tubb3(B)_Hoechst(B)_20x_merge-comp.jpg?width=604&name=Colour%20webinar%20with%20it-bio%20ioGlutamatergic%20Neurons_VGLUT2(G)_MAP2(R)_Tubb3(B)_Hoechst(B)_20x_merge-comp.jpg)
Cell culture hacks | human iPSC-derived glutamatergic neurons
Read this blog on glutamatergic neuron cell culture for our top tips on careful handling, cell plating and media changes to achieve success from the outset.
.png?width=1860&height=1260&name=bit.bio_3x2_ioGlutamatergic%20Neurons_MAP2_Hoescht_x20_hi.res%20(1).png)
ioDisease Model Cells
ioDisease Model Cells
ioDisease Model Cells
ioWild Type Cells
CRISPR-Ready ioCells
ioDisease Model Cells
ioDisease Model Cells
ioDisease Model Cells
ioDisease Model Cells
Wild type and isogenic disease model cells: a true comparison.
Further your disease research by pairing our wild type Cells with isogenic disease models.
